Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas

Cancer

Volumn 77, Issue 2, 1996, Pages 373-380

  Wakimoto, Hiroaki ^a   Aoyagi, Masaru ^a   Nakayama, Takeo ^b   Nagashima, Goro ^a   Yamamoto, Shinji ^a   Tamaki, Masashi ^a   Hirakawa, Kimiyoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

astrocytoma; Ki 67; monoclonal antibody MIB 1; proliferative potential; survival

Indexed keywords

CELL ANTIGEN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY KI 67;

ADULT; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ASTROCYTOMA; BRAIN NEOPLASMS; CELL DIVISION; CHILD; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS;

EID: 0030064838     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960115)77:2<373::AID-CNCR21>3.0.CO;2-Y     Document Type: Article

References (46)

1. Black PM. Brain tumors (second of two parts). N Engl J Med 1991;324:1555-64.
2. Wilson CB. Brain tumors. N Engl J Med 1979;300:1469-71.
3. Ganju V, Jenkins RB, O'Fallon JR, Scheithauer BW, Ransom DT, Katzmann JA, et al. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, and flow cytometric, cytogenetic, and molecular markers. Cancer 1994;74:920-7.
4. Hoshino T, Ahn D, Prados MD, Lamborn K, Wilson CB. Prognostic significance of the proliferative potential of intracranial gliomas measured by broraodeoxyuridine labeling. Int J Cancer 1993;53:550-5.
5. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer 1987;59:1617-25.
6. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985;56:1106-11.
7. Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P. Grading of astrocytomas. A simple and reproducible method. Cancer 1988;62:2152-65.
8. Nelson JS, Tsukada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N. Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas. Cancer 1983;52:550-4.
9. Paulus W, Peiffer J. Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 1989;64:442-7.
10. Shibuya M, Ito S, Miwa T, Davis RL. Wilson CB, Hoshino T. Proliferative potential of brain tumors. Analyses with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nuclear organizer region counts. Cancer 1993:71:199-206.
11. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
12. Gerdes J. An immunohistochemical method for estimating cell growth fractions in rapid histopathological diagnosis during surgery. Int J Cancer 1985;35:169-71.
13. Giangaspero F, Doglioni C, Rivano MT, Pileri S, Gerdes J, Stein H. Growth fraction in human brain tumors defined by the monoclonal antibody Ki-67. Acta Neuropathol 1987;74:179-82.
14. Louis DN, Edgerton S, Thor AD, Heldley-Whyte ET. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study. Acta Neuropathol 1991;81:675-9.
15. Gerdes J, Becker MHG, Key G, Cattoretti G. Immunohistological detection of tumor growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 1992;168:85-6.
16. Shi S-R, Key ME, Kalra KL. Antigen retrieval in formalinfixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 1991;39:741-8.
17. Shin R-W, Iwaki T, Kitamoto T, Tateishi J. Methods in laboratory investigation. Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues. Lab Invest 1991;64:693-702.
18. Kleihues P, Burger PC, Scheithauer BW. Histologic typing of tumors of the central nervous system. New York: Springer-Verlag, 1993.
19. Nagashima G, Aoyagi M, Wakimoto H, Tamaki M, Ohno K, Hirakawa K. Immunohistochemical detection of progesterone receptors and the correlation with the Ki-67 labeling indices in paraffin-embedded sections of meningiomas. Neurosurgery 1995;37:478-83.
20. Salmon I, Dewitte O, Pasteels J-L, Flament-Durand J, Brotchi J, Vereerstraeten P, et al. Prognostic scoring in adult astrocytic tumors using patient age, histopathological grade, and DNA histogram type. J Neurosurg 1994;80:877-83.
21. Kamofsky DA, Burchenal IH, Armistead GC, Southam CM, Bernstein JL, Craver LF, et al. Triethylene melamine in the treatment of neoplastic disease. Arch Intern Med 1951;87:477-516.
22. Harrell FJ. The PHGLM procedure, 5th ed. Cary, NC: SAS Institute, Inc, 1986:437-66.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
24. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
25. Cox DR. Regression models and Me tables. J R Stat Soc (B) 1972;34:187-220.
26. Coons SW, Johnson PC, Pearl DK. Prognostic significance of flow cytometry deoxyribonucleic acid analysis of human astrocytomas. Neurosurgery 1994;35:119-26.
27. Devaux BC, O'Fallon JR, Kelly PJ, Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993;78:767-75.
28. Kreth FW, Warnke PC, Scheremet R, Ostertag CB. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg 1993;78:762-6.
29. Vecht CJ, Avezaat CJJ, van Putten WLJ, Eijkenboom WMH, Stefanko SZ. The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry 1990;53:466-71.
30. Montine TJ, Vandersteenhoven JJ, Aguzzi A, Boyko OB, Dodge RK, Kerns B-J, et al. Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery 1994;34:674-9.
31. Pigott TJ, Lowe JS, Palmer J. Statistical modelling in analysis of prognosis in glioblastoma multiforme: a study of clinical variables and Ki-67 index. Br J Neurosurg 1991;5:61-6.
32. Ritter AM, Sawaya R, Hess KR, Levin VA, Bruner JM. Prognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme. Neurosurgery 1994;35:192-8.
33. Karamitopoulou E, Perentes E, Diamantis I, Maraziotos T. Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47-54.
34. Onda K, Davis RL, Shibuya M, Wilson CB, Hoshino T. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 1994;74:1921-6.
35. Lopez F, Belloc F, Lacombe F, Dumain P, Reifferes J, Bernard P, et al. The labeling of proliferating cells by Ki67 and MIB-1 antibodies depends on the binding of a nuclear protein to the DNA. Exp Cell Res 1994;210:145-53.
36. Onda K, Davis RL, Wilson CB, Hoshino T. Regional differences in bromodeoxyuridine uptake, expression of Ki-67 protein, and nucleolar organizer region counts in glioblastoma multiforme. Acta Neuropathol 1994;87:586-93.
37. Sjöstrand FS, Barajas L. Effect of modifications in conformation of protein molecules on structure of mitochondrial membranes. J Ultrastruct Res 1968;25:121-55.
38. Hirakawa K, Suzuki K, Ueda S, Nakayama Y, Yoshino E, Ibayashi N, et al. Multivariate analysis of factors affecting post-operative survival in malignant astrocytoma. Importance of DNA quantification. J Neurooncol 1984;2:331-40.
39. Kelly PJ, Hunt C. The limited value of cytoreductive surgery in elderly patients with malignant gliomas. Neurosurgery 1994;34:62-7.
40. Chozick BS, Weicker ME, Pezzuilo JC, Jackson CL, Finkelstein SD, Ambler MW, et al. Pattern of mutant p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 1994;73:406-15.
41. Lang FF, Miller DC, Koslow M, Newcomb EW. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic rumors. J Neurosurg 1994;81:427-36.
42. Schiffer D, Cavalla P, Chiò A, Giordana MT, Marino S, Mauro A, et al. Tumor cell proliferation and apoptosis in medulloblastoma. Acta Neuropathol 1994;87:362-70.
43. Nagano N, Sasaki H, Aoyagi M, Hirakawa K. Invasion of experimental rat brain tumor: early morphological changes following microinjection of C6 glioma cells. Acta Neuropathol 1993;86:117-25.
44. Rutka JT, Apodaca G, Stern R, Rosenblum M. The extracellular matrix of the central and peripheral nervous systems: structure and function. J Neurosurg 1988;69:155-70.
45. Takamiya Y, Brem H, Ojeifo J, Mineta T, Martuza RL. AGM-1470 inhibits the growth of human glioblastoma cells in vitro and in vivo. Neurosurgery 1994;34:869-75.
46. Hoshino T, Prados M, Wilson CB, Cho KG, Lee K-S, Davis RL. Prognostic implications of the bromodeoxyuridine labeling index of human gliomas. J Neurosurg 1989;71:335-41.